The interest in proprotein convertase subtilisin/kexin type 9 (PCSK9) as a lipid-lowering target arose at the beginning of the present century after the identification of several families with familial hypercholesterolemia (FH) who carried gain-of-function mutations in the gene encoding PCSK9. Here, PCSK9 is linked to familial hyperaldosteronism.